SIM01 represents a safe and promising remedy for post-acute Covid-19 syndrome (PACS).
![Can Probiotics and Prebiotics Provide Relief for Long COVID? Can Probiotics and Prebiotics Provide Relief for Long COVID?](https://images.medindia.net/health-images/1200_1000/standing-sitting-lying-down-how-to-take-your-pills.jpg)
A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY)
Go to source) "Treatment with SIM01 alleviates multiple symptoms of PACS. Our findings have implications on the management of PACS through gut microbiome modulation," said the researchers in the paper published in The Lancet Infectious Diseases. From June 2021 to August 2022, the researchers randomly assigned 463 adult long-Covid patients at a single hospital in a 1:1 ratio to receive SIM01 or a Vitamin C placebo by mouth twice daily for 6 months.
‘A novel experimental drug has the capability to modify the gut microbiome and alleviate various long Covid symptoms. #longcovid #covidsymptoms’
![pinterest](https://images.medindia.net/icons/news/social/pinterest.png)
The median interval between infection and random assignment was 4 months.Nearly one third of patients (31 percent) had been hospitalised during their infections.At six months, significantly higher proportions of the SIM01 group reported an improvement in fatigue, memory loss, difficulty concentrating, gastrointestinal upset, and general unwellness than the placebo group. ![twitter](https://images.medindia.net/icons/news/social/twitter.png)
![facebook](https://images.medindia.net/icons/news/social/facebook.png)
![whatsapp](https://images.medindia.net/icons/news/social/whatsapp.png)
![linkedin](https://images.medindia.net/icons/news/social/linkedin.png)
![pinterest](https://images.medindia.net/icons/news/social/pinterest.png)
Advertisement
"We identified favourable changes in the gut microbiome, including increased bacterial diversity and short-chain acid-producing bacteria and decreased resistome in the SIM01 group but not placebo group after 6 months of treatment, as plausible mechanisms to account for the clinical improvement. SIM01 is a safe and promising treatment for PACS, which is worth further confirmation in a pragmatic, multi-centre trial. Our findings on gut microbiota provided plausible mechanisms to account for the observed clinical benefits," the researchers said.
Reference:
- A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY) - (https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00685-0/fulltext)